Late last month, Adlai Nortye raised $57.5 million from its U.S. IPO on the Nasdaq and $40 million from a concurrent private placement, bringing in a total of $97.5 million. The FDA approved Tofidence (tocilizumab-bavi) intravenous formulation, a biosimilar monoclonal antibody referencing Actemra, on September 29.